These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 14751897)

  • 21. Treatment of late-state HIV infection.
    Millard PS
    J Fam Pract; 1997 Feb; 44(2):132-4. PubMed ID: 9040512
    [No Abstract]   [Full Text] [Related]  

  • 22. [Non-nucleoside reverse transcriptase inhibitor as a fully viable alternative. Strong therapy start without protease inhibitor].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():30-3. PubMed ID: 10863307
    [No Abstract]   [Full Text] [Related]  

  • 23. Antiretroviral therapy: naïve patients and early therapy.
    Gallant JE
    Hopkins HIV Rep; 2001 Mar; 13(2):3-4, 15. PubMed ID: 12184262
    [No Abstract]   [Full Text] [Related]  

  • 24. Drug combinations for HIV: what's new?
    Scourfield A; Waters L; Nelson M
    Expert Rev Anti Infect Ther; 2011 Nov; 9(11):1001-11. PubMed ID: 22029520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy.
    Lima VD; Hogg RS; Harrigan PR; Moore D; Yip B; Wood E; Montaner JS
    AIDS; 2007 Mar; 21(6):685-92. PubMed ID: 17413689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial.
    MacArthur RD; Chen L; Mayers DL; Besch CL; Novak R; van den Berg-Wolf M; Yurik T; Peng G; Schmetter B; Brizz B; Abrams D;
    Control Clin Trials; 2001 Apr; 22(2):176-90. PubMed ID: 11306155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing resistance costs of antiretroviral therapies via measures of future drug options.
    Jiang H; Deeks SG; Kuritzkes DR; Lallemant M; Katzenstein D; Albrecht M; DeGruttola V
    J Infect Dis; 2003 Oct; 188(7):1001-8. PubMed ID: 14513420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term effectiveness of highly active antiretroviral therapy (HAART) in perinatally HIV-infected children in Denmark.
    Bracher L; Valerius NH; Rosenfeldt V; Herlin T; Fisker N; Nielsen H; Obel N
    Scand J Infect Dis; 2007; 39(9):799-804. PubMed ID: 17701719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States.
    Persaud D; Palumbo P; Ziemniak C; Chen J; Ray SC; Hughes M; Havens P; Purswani M; Gaur AH; Chadwick EG;
    J Infect Dis; 2007 May; 195(10):1402-10. PubMed ID: 17436219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Reverse transcriptase inhibitors, protease inhibitors].
    Tachikawa N
    Nihon Rinsho; 2012 Apr; 70(4):579-95. PubMed ID: 22568138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA.
    Raffi F; Bonnet B; Ferré V; Esnault JL; Perré P; Reliquet V; Leautez S; Bouillant C; Vergnoux O; Weinbreck P
    Clin Infect Dis; 2000 Nov; 31(5):1274-8. PubMed ID: 11073763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [HIV-1 resistance against antiretroviral agents].
    Asjø B; Ulvestad E
    Tidsskr Nor Laegeforen; 2001 Nov; 121(29):3421-4. PubMed ID: 11826790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiretroviral therapy 2010 update: current practices and controversies.
    Grant M; Samuel R; Bettiker RL; Suh B
    Arch Pharm Res; 2011 Jul; 34(7):1045-53. PubMed ID: 21811910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain.
    de Mulder M; Yebra G; Martín L; Prieto L; Mellado MJ; Rojo P; Muñoz-Fernández MÁ; Jiménez de Ory S; Ramos JT; Holguín A;
    J Antimicrob Chemother; 2011 Oct; 66(10):2362-71. PubMed ID: 21810838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Recent development of novel reverse transcriptase inhibitors and protease inhibitors against HIV-1 infection].
    Koh Y
    Nihon Rinsho; 2010 Mar; 68(3):512-9. PubMed ID: 20229800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors.
    Tavel JA; Miller KD; Masur H
    Clin Infect Dis; 1999 Mar; 28(3):643-76. PubMed ID: 10194094
    [No Abstract]   [Full Text] [Related]  

  • 38. Immune reconstitution syndromes in human immuno-deficiency virus infection following effective antiretroviral therapy.
    Behrens GM; Meyer D; Stoll M; Schmidt RE
    Immunobiology; 2000 Aug; 202(2):186-93. PubMed ID: 10993293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Research on the selective kinetics of HIV-1 nucleoside reverse transcriptase inhibitor drug resistance-associated mutations among 4 AIDS patients receiving highly active antiretroviral therapy].
    Li J; Jiao LY; Li HP; Li L; Liu YJ; Zhuang DM; Liu SY; Bao ZY; Li H; Wang Z; Li JY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Aug; 29(8):794-800. PubMed ID: 19103117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and durability of non-nucleoside reverse transcriptase inhibitor-based therapy in HIV clinical practice.
    Kan VL
    AIDS; 2007 Apr; 21(7):880-2. PubMed ID: 17415048
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.